title: Pyoderma gangrenosum possibly triggered by adalimumab.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kikuchi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Hiraiwa
authors.forename: Takenobu
authors.initials: T
authors.lastname: Ohashi
authors.forename: Yuka
authors.initials: Y
authors.lastname: Hanami
authors.forename: Masataka
authors.initials: M
authors.lastname: Satoh
authors.forename: Hideo
authors.initials: H
authors.lastname: Takenoshita
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Yamamoto
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D011239:Prednisolone; D000068879:Adalimumab